Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

BACKGROUND: Teriflunomide, an oral disease-modifying therapy in development for patients with relapsing forms of multiple sclerosis (RMS), was well tolerated and effective in reducing magnetic resonance imaging (MRI) lesions in 179 RMS patients in a phase 2 36-week, placebo-controlled study. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Confavreux, Christian, Li, David K, Freedman, Mark S, Truffinet, Philippe, Benzerdjeb, Hadj, Wang, Dazhe, Bar-Or, Amit, Traboulsee, Anthony L, Reiman, Lucy E, O’Connor, Paul W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2012
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573681/
https://www.ncbi.nlm.nih.gov/pubmed/22307384
http://dx.doi.org/10.1177/1352458512436594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573681/
https://www.ncbi.nlm.nih.gov/pubmed/22307384
http://dx.doi.org/10.1177/1352458512436594

Ejemplares similares